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Breach Delivery: Increased Solute 
Uptake Points to a Defective Skin 
Barrier in Atopic Dermatitis
W.H. Irwin McLean1 and Peter R. Hull1
Evidence is now emerging for enhanced penetration of chemical solutes into 
uninvolved skin of atopic dermatitis patients. Along with the recent discovery 
of prevalent null mutations in the gene encoding filaggrin, a protein essential 
for stratum corneum formation, these data point to an innate epidermal-barrier 
defect in atopy.
Journal of Investigative Dermatology (2007) 127, 8–10. doi:10.1038/sj.jid.5700609
Atopic dermatitis (AD, “eczema”) 
has increased in prevalence in recent 
decades; it now affects 15%–20% of 
children in the developed world alone 
and affects all races to differing degrees. 
The disease is a classical complex trait 
— it is clearly highly heritable but with 
reduced penetrance, and there is strong 
evidence for environmental influences 
(Morar et al., 2006). Furthermore, the 
disease impacts on other areas of medi-
cine, as a high percentage of eczema 
patients develop a range of additional 
allergic conditions, including food aller-
gies, asthma, and rhinitis, often occur-
ring in a temporal “program” known as 
the atopic march (Spergel and Paller, 
2003). AD causes considerable mor-
bidity and significantly affects quality 
of life. This is particularly the case for 
severe AD persisting into adulthood. 
Establishing the contributing etiological 
factors for this complex disease — both 
genetic predisposing factors and envi-
ronmental trigger factors — is of para-
mount importance in the development 
of new, possibly more effective treat-
ments and/or preventative regimens. 
Given that the skin is inflamed within 
an AD lesion, there is an obvious immu-
nological component in the disease; 
however, recent evidence coming from 
both molecular genetics and functional 
analysis strongly suggests that a skin 
barrier defect is the necessary cause in a 
considerable proportion of atopy cases.
Although there is considerable func-
tional evidence for impaired skin bar-
rier function within active lesional skin 
of AD patients, as seen, for example, 
by increased trans-epidermal water 
loss, the situation has been less clear in 
studies of uninvolved skin, where the 
results have been somewhat contradic-
tory. Ivone Jakasa and colleagues in 
Amsterdam and Rome (2007) present 
conclusive, statistically significant evi-
dence for enhanced uptake of an entire 
series of polyethylene glycols, covering 
molecular weights in the range 150–
590 daltons, in non-lesional skin of AD 
patients. This result is further supported 
by recently published evidence from 
the same research group for enhanced 
uptake of sodium lauryl sulfate in non-
lesional AD skin, based on the use of 
similar methods (Jakasa et al., 2006). 
Genji Imokawa’s group and collabo-
rators in Japan, using a photoacoustic 
spectography system, showed enhanced 
penetration of both a lipophilic and 
a hydrophilic dye through clinically 
normal skin of AD patients as com-
pared with control subjects. In addi-
tion, they showed a significant correla-
tion between penetration rates for the 
hydrophilic dye and elevated IgE levels 
for patients with severe AD (Hata et al., 
2002). Together, these reports strongly 
support the hypothesis that patients with 
AD have an inherent skin barrier defect, 
probably due to one or a combination 
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of genetic mutations, whether or not a 
particular area of their skin has active 
eczema at any given time, implying that 
this is the main predisposing factor for 
the development of AD.
Recently, it has been shown that null 
mutations in the filaggrin gene are the 
cause of ichthyosis vulgaris (Smith et al., 
2006) and that these same mutations 
are highly prevalent in some European 
populations where up to 9%–10% of 
individuals are heterozygous carriers, 
that is, they are haploinsufficient for 
filaggrin. It was subsequently shown 
that these mutations are also an impor-
tant genetic predisposing factor for AD 
(Palmer et al., 2006). Further studies 
have now confirmed the strong asso-
ciation of filaggrin-null alleles and AD, 
as well as the other allergic conditions 
that make up the atopic march. At the 
time of writing, the papers published 
so far report 15 forms of replication for 
this association, and so the AD–filag-
grin story is already unusually robust 
in the field of complex-trait genetics. 
Profilaggrin is the major protein of 
which keratohyalin granules are com-
posed, and when this highly abundant 
polyprotein is proteolytically cleaved 
in the uppermost granular cells, the lib-
erated filaggrin peptides aggregate the 
keratin cytoskeleton and bring about 
cell compaction to make the squames. 
Therefore, this gene–protein system is 
critical in the formation of the stratum 
corneum, the cell compartment within 
which the epidermal-barrier function 
resides. Haploinsufficiency for filag-
grin in mutation carriers, or complete 
loss in homozygotes or compound het-
erozygotes, leads to impaired barrier 
formation, which manifests as varying 
degrees of dry skin, ichthyosis, and/or 
eczema. A further function of filag-
grin has also been suggested, whereby 
it may be broken down in the stra-
tum corneum into hygroscopic amino 
acids and derivatives thereof that act 
as a “natural moisturizing substance” 
(Rawlings and Harding, 2004). Thus, 
filaggrin deficiency may spell double 
trouble — impaired formation of the 
stratum corneum as well as a lack of 
the skin’s built-in humectant.
The extracellular lipid lamellae also 
play an important role in skin barrier 
function. Ceramides are the most abun-
dant of the lipids in the stratum corneum. 
In AD, ceramide levels are reported to be 
decreased and lipid packaging altered 
(Imokawa et al., 1991; Pilgram et al., 
2001). Sphingomyelin deacylase activ-
ity has been found to be increased in AD 
(Hara et al., 2000). This enzyme hydro-
lyzes sphingomyelin to sphingosylphos-
phorylcholine and free fatty acid instead 
of ceramide. This is suggested to explain 
the decreased ceramide in AD. Is there 
possibly a link between filaggrin and 
lipid metabolism? The analysis of epider-
mal lipids in subjects of known filaggrin 
genotype may shed light on this impor-
tant aspect of the skin barrier in eczema.
Here, Jakasa and co-workers (2007) 
did not genotype their small AD cohort 
for filaggrin-null variants, as their cur-
rent study predates the publication of 
the role of this gene in AD. Interestingly, 
they excluded AD patients who had con-
comitant signs of ichthyosis vulgaris and 
so may have eliminated some or all filag-
grin-null carriers from their cohort. It will 
be fascinating to combine the two func-
tional assays they have developed for 
measuring epidermal solute transfer with 
filaggrin genotyping in future AD patient 
cohorts. Because the experiments report-
ed here showed a breach in skin barrier 
function in all the AD patients examined 
as compared with control subjects, one 
would predict that the AD patients who 
do not carry filaggrin mutations would 
still have impaired barrier function. It 
will also be interesting to see whether 
combining genetic testing with solute 
uptake measurement methods can help 
stratify AD. The strongest filaggrin asso-
ciations are currently being observed in 
patients with hospital- or dermatologist-
diagnosed eczema, which represents the 
moderate-to-severe end of the disease 
spectrum. Do these patients with more 
severe AD have consistently worse bar-
rier impairment, or does all AD behave 
similarly in terms of barrier function 
regardless of filaggrin status?
Another interesting question con-
cerns looking at bigger AD cohorts 
with the use of Jakasa and colleagues’ 
(2007) methodology. Are there AD 
patients out there who do not have an 
obvious barrier impairment? The study 
by Jakasa et al. (2007) suggests that this 
may not be the case, but a larger study 
is needed to address this, especially 
one in which patients with mild, mod-
erate, and severe eczema are included 
in reasonable numbers. This might tell 
us whether or not there is a propor-
tion of AD in which barrier function 
is not so important and in which per-
haps a primarily immunological defect 
predominates. The current feeling 
in the AD field is that a barrier defect 
is a sufficient cause of AD, but one 
should not dismiss a primary immuno-
logical/allergy hypothesis out of hand. 
Genome-wide linkage studies have 
shown that AD susceptibility is hetero-
geneous, and although filaggrin may be 
important in a good proportion of more 
severe AD, it is certainly not the only 
gene that will be linked to this com-
plex trait. With the recent completion 
of the human genome sequence, the 
haplotype map, and advances in high-
throughput sequencing and typing of 
polymorphisms, we will hopefully see 
the emergence of other consistently 
replicable atopy gene associations in 
the near future. Once the genetic pic-
ture becomes more complete, the envi-
ronmental trigger factors that have led 
to the obviously increased incidence 
of AD in recent decades need to be 
addressed. Then, the next barrier to 
breach will be that of translating all 
this knowledge into more rational, and 
hopefully more effective, treatments for 
eczema and related atopic conditions.
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